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Molecular studies have shown that multiple myeloma is a highly genetically heterogonous disease which may manifest itself as
any number of diverse subtypes each with variable clinicopathological features and outcomes. Given this genetic heterogeneity, a
universal approach to treatment of myeloma is unlikely to be successful for all patients and instead we should strive for the goal of
personalised therapy using rationally informed targeted strategies. Current DNA sequencing technologies allow for whole genome
and exome analysis of patient myeloma samples that yield vast amounts of genetic data and provide a mutational overview of the
disease. However, the clinical utility of this information currently lags far behind the sequencing technology which is increasingly
being incorporated into clinical practice. This paper attempts to address this shortcoming by proposing a novel genetically based
“traffic-light” risk stratification system for myeloma, termed the RAG (Red, Amber, Green) model, which represents a simplified
concept of how complex genetic data may be compressed into an aggregate risk score. The model aims to incorporate all known
clinically important trisomies, translocations, and mutations in myeloma and utilise these to produce a score between 1.0 and 3.0
that can be incorporated into diagnostic, prognostic, and treatment algorithms for the patient.
1. Introduction
Molecular studies have made it apparent that multiple
myeloma is not a single disease entity but rather a collection
of genetically diverse disease subtypes that manifest clinically
as the clonal proliferation of plasma cells. With this, it is
clear that a universal treatment approach is not sufficient
and that patient management should be targeted towards
the specific genetic disease subtype(s) a patient harbours.
To fully achieve this, along with the somewhat established
approaches of conventional cytogenetics and fluorescent in
situ hybridisation (FISH), the myeloma genome from each
individual will likely require sequence analysis as part of
a standardized approach, with an algorithm/model then
existing to elucidate clinically valuable meanings from the
findings. This paper therefore proposes a concept myeloma
“traffic light” risk stratification model, named the RAG (Red-
Amber-Green) model, which aims to simplify data produced
from genetic analysis into an accessible and intuitive form
to inform disease risk stratification in the clinical setting. As
a concept, the RAG model is designed to begin the process
of attempting to integrate complex genetic information,
particularly derived from sequencing technologies, into a
simple risk stratification system.
2. Challenge of Designing Genetic Risk
Stratification Models
Despite a consensus within the field that the integration
of genetic information into the diagnosis, treatment, and
prognosis of myeloma would be of great benefit, there is
currently no universally accepted system to achieve this.
The main challenge in designing such a model for clinical
use is that often an abundance of complex data must be
simplified into an intuitive and useful form whilst remaining
valid and applicable. This balance is difficult to obtain, as
models which are too complex become clinically unintel-
ligible whereas those which are too simple lose accuracy
and informative power. As a variety of molecular techniques
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are available to analyse the myeloma genome, a proposed
genetic based model must be able to either incorporate the
findings from a range of methods or be specifically designed
to unite one. For reasons discussed hereafter, the RAGmodel
is designed to accommodate multiple analytical methods
but crucially expands on other risk stratification systems
by attempting to accommodate whole genome sequencing
(WGS)/whole exome sequencing (WES) data, as although
these techniques are currently still highly experimental and
cannot currently be used to accurately inform treatment
decisions or risk/prognosis, it appears likely that due to their
power and increasing accessibility these techniques will play
a key role in the workup of myeloma patients in the future.
Furthermore, although the RAG model is presented here as
a concept for risk stratification, the benefits of which are to
optimize outcomes and stratify treatment regimes in order to
minimize toxicity, it is possible that in the future such amodel
will inform many different areas of myeloma medicine such
as identifying new disease biomarkers and therapeutic targets
and helping better genetically categorise/diagnose myeloma
disease subtypes. The advances that these areas would bring
to myeloma treatment alongside risk stratification make
it even more pressing for models to be developed which
accurately interpret and utilise genetic information.
3. Current Methods of Myeloma Risk
Stratification and Prognostication
To establish a context for the requirement for a genetic risk
stratification model, such as the RAG model, a literature
review covering current myeloma risk stratification and
prognostication follows.
3.1. International Staging System forMyeloma. For anymalig-
nancy to have a simple, accurate, and easily applicable
universal staging system to inform prognosis is of obvious
benefit.The first such staging system for myeloma, developed
by Durie and Salmon in 1975 [1], used standard laboratory
measurements and imaging to predict patient outcomes.
This system was based mainly on measuring tumour burden
and although still a useful means for achieving this today
with improving treatments and extended patient survival
the system proves less reliable for modern day prognosis.
Subsequent to the Durie and Salmon model, the importance
of the prognostic factors of serum 𝛽
2
-microglobulin (S𝛽
2
M)
and serum albumin, which reflect disease burden plus renal
function and patient “fitness,” respectively, emerged and led
to the development of the international staging system (ISS)
for myeloma (Table 1) [2]. The ISS is extremely convenient
to use and proves applicable for prognostication across
the majority of myeloma treatment settings. However, with
the increasing use of molecular techniques to analyse the
myeloma genome, there is a necessity for the integration of
genetic information into the ISS to contemporise the system,
especially as the system is recognised as being limited in
power to detect the very highest-risk patients. With this,
the RAG model is presented here as a starting point, not
to supplant the ISS, but to put forward a concept on how
Table 1: The international staging system for myeloma [2].
Stage Criteria Median survival(months)
I
Serum 𝛽
2
-microglobulin
<3.5mg/L and serum albumin
≥3.5 g/dL
62
II Neither stage I or III∗ 44
III Serum 𝛽2-microglobulin
≥5.5mg/L 29
∗There are two categories for stage II: serum 𝛽2-microglobulin <3.5mg/L
but serum albumin <3.5 g/dL; or serum 𝛽2-microglobulin 3.5 to <5.5mg/L
irrespective of the serum albumin level.
the system may be supplemented through the integration of
genetic information.
3.2. Myeloma Risk Stratification via FISH. With the ISS
proving thatmeasurements of disease burden, renal function,
and patient “fitness” can accurately guidemyelomaprognosis,
a number of studies postulated whether FISH could be
used to similar effect. In 2009, the International Myeloma
Working Group (IMWG) evaluated the data published on
the role of FISH in myeloma prognostication to formulate a
consensus [3]. From their findings, the IMWGrecommended
that at a bare minimum a FISH panel testing for t(4;14),
t(14;16), and del(17p) should be sought for all patients at
diagnosis as these aberrations are associated with impaired
survival and can genetically define a patient with high-
risk disease. Since this recommendation, additional data has
suggested that FISH analysis for +1q and t(14;20) should
also be considered as these lesions would provide a more
comprehensive assessment and further aid risk stratification
[4]. As myeloma is often associated with gross chromosomal
abnormalities, such as trisomies and translocations [5], the
above recommendations state that conventional karyotyping
should be combined with FISH analysis where possible as the
technique provides quantitative chromosomal information
which will supplement the more subtle structural changes
detected by FISH. Despite this, if only one technique is
employed, it is recommended that FISH be chosen due to the
more specific and clinically useful information provided [6].
Recently, an important study conducted by Boyd et al.
used outcome data from the Medical Research Council
(MRC) myeloma IX trial to conduct multivariate analysis
on the interaction of genetic aberrations identified via a
comprehensive FISH panel [4]. Based on their findings, the
genetic lesions associated with both short progression free
survival (PFS) and overall survival (OS) included +1q21,
del(17p13), and an adverse IGH@ translocation group incor-
porating t(4;14), t(14;16), and t(14;20). The study found
that these adverse lesions often cosegregated and that an
association between the accumulation of these lesions and
worsened PFS and OS existed. The study then developed
a novel risk stratification system by allocating patients into
high-, intermediate-, and favourable-risk groups based on
their FISH characterisation. The favourable-risk group was
defined by an absence of +1q, del(17p13), and adverse IGH@
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translocations, the intermediate-risk group harbours just one
of these adverse lesions, and the high-risk group is defined by
the cosegregation of >1 adverse lesion. This grouping proved
accurate for prognostication and was independent of the
ISS. The observation within this study that an accumulation
of genetic lesions worsens outcome suggests that no one
adverse finding on its own can define a high-risk group
and implies that if FISH was to be used for risk stratifica-
tion, a clearly defined and comprehensive panel would be
required.
3.3. Combining FISH and the ISS for Myeloma Risk Strat-
ification. As the ISS considers different factors to FISH,
several groups have attempted to combine these twomethods
to adjudge whether a more optimal prognostic model can
be developed. These studies are important as any model
utilising genetic data for prognosis will ultimately require
some consideration of tumour burden and host “fitness”
to optimise accuracy. Boyd et al., using their initial risk
stratification groups from theMRC IX trial, integrated the ISS
and identified that an ultrahigh-risk group could be defined
at diagnosis by ISS stages II or III plus >1 of their defined
adverse lesions [4]. This ultrahigh-risk group constituted
13.8% of patients in the study and strongly predicted a poor
outcome with median PFS and OS at 9.9 months and 19.4
months, respectively. Similarly, in a French study conducted
via the Intergroupe Francophone du Mye´lome, 1064 young
(<66) myeloma patients enrolled in homogenous therapeutic
trials were prognostically assessed via FISH analysis [7].
Integration of their findings with the ISS revealed that a high-
risk group consisting of t(4;14) or del(17) lesions and a high
S𝛽
2
M accurately predicted short survival to a greater degree
than the ISS alone. Providing similar evidence, retrospective
analysis of 2642 patients comprehensively analysed using
FISH from the IMWG database showed that combining
both t(4;14) and del(17p) along with the ISS significantly
improved PFS and OS prognostication [8]. Furthermore,
recent data analysed from three separate myeloma trials has
shown that patients with t(4;14) and/or del(17p) in addition
to ISS stage III and/or high levels of lactate dehydrogenase
(LDH) are at high risk of progression-related death despite
modern treatment strategies [9]. These findings demonstrate
that the prognostic accuracy of the ISS can be enhanced
through the incorporation of both biochemical and genetic
parameters.
3.4. Limitations to FISH in Myeloma Risk Stratification.
Despite the contribution FISH analysis has made to improv-
ing myeloma understanding, a particular limitation to the
technique is that it may only detect predefined genetic lesions
determined by the specific probes employed. As the majority
of key myeloma FISH lesions are already likely defined,
this limitation is unlikely to prevent a well-constructed
FISH library from becoming part of a universally accepted
prognostic/risk stratification system.However, this limitation
does prevent FISH from being utilised as a parallel screening
tool to identify unknown genetic aberrations across thewhole
genome, an attribute which sequencing technology possesses
and one which would improve therapeutic development and
biological understanding. This point is well demonstrated
by WGS recently identifying previously unobserved BRAF
mutations in seven out of 161 (4%)myeloma patients screened
with the technique [10]. These patients harbouring BRAF
mutations may therefore benefit from treatment with newly
developed BRAF inhibitors, drugs that in some instances
have shown marked clinical activity [11]. Further to this
limitation, some patientswith “poor” prognostic FISH lesions
have shown very good survival [7, 12, 13], bringing the speci-
ficity of these FISH findings in certain instances somewhat
into question. Due to this, it appears the application of FISH
to define risk needs refinement and/or supplementation as if
current methods were solely relied upon there is the potential
risk of patient harm through either over- or undertreating
with chemotherapy.
3.5. Myeloma Risk Stratification via GEP. As FISH proved
useful in myeloma prognostication, studies began to assess
whether gene expression profiling (GEP) could also be used
effectively. Shaughnessy et al. first assessed 532 newly diag-
nosedmyelomapatientswithGEP and, using log-rank tests of
expression quartiles, identified 70 genes which were linked to
shorter durations of remission, event-free survival (EFS), and
OS [14]. Interestingly, they found that 30%of these geneswere
mapped to chromosome 1, with the majority of upregulated
genes on 1q and downregulated genes on 1p. Using a ratio of
mean upregulated to downregulated gene expression, a high-
risk score was defined which proved to be an independent
predictor of outcome endpoints in multivariate analysis
that included the ISS. To further their work, multivariate
discriminate analysis was performed which revealed that a
17-gene subset of the original 70 genes could predict out-
comes as well as their original findings. The study therefore
concluded that GEP could be used to accurately define high-
risk disease through a genetic signature, a feature which may
guide future therapeutic interventions by identifying over- or
underexpressed genes/pathways.
A second study conducted by Decaux et al. investi-
gated the GEP of 182 myeloma patients and identified
the 15 strongest genes associated with length of survival
[15]. These genes were then used to formulate a risk score
which stratified patients into a high-risk group, characterised
by the overexpression of genes involved in the cell cycle
and cell cycle surveillance, and a low-risk group, charac-
terised by a heterogeneous GEP pattern with a concomitant
hyperdiploid signature. To validate the model, it was first
tested in a set of 68 patients and then secondly in three
independent myeloma cohorts totalling 853 patients. The
kaplan-Meier estimates of OS at three years for the low-
and high-risk groups were 90.5% and 47.4%, respectively,
and were independent of traditional prognostic factors such
as those of the ISS. This study again demonstrated that
the genetic signature of myeloma could be used to predict
survival.
3.6. Limitations to GEP in Myeloma Risk Stratification.
Interestingly, of the 17 and 15 genes identified by the two
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aforementioned studies, none were shared, a finding which
demonstrates the genetic complexity of myeloma. Further-
more, in these GEP studies, as for FISH analysis, the gene
signatures used to define high-risk disease were not always
specific for a given clinical outcome, a problem which
may again lead to potential over- or undertreatment with
chemotherapy. Additionally, gene mapping arrays only anal-
yse the genetic signature of the predominant clone, whereas
WGS can provide semiquantitative analysis of the size of the
clonal population carrying a given aberration allowing for
characterisation of disease substructure [16]. Furthermore,
GEP is also required to be combined with FISH analysis
to detect certain important prognostic lesions, as some, for
example, del(17p), cannot be assayed by the technique. From
the cumulative information on the use of GEP, it is clear
that the technique has the potential to contribute towards
myeloma prognosis. However, the technique is still largely
experimental and not widely available and several issues
require addressing before this technique becomes a practical
option.
3.7.mSMARTPrognostic Factors andRisk StratificationModel.
Themayo stratification of myeloma and risk-adapted therapy
model (mSMART) is a set of consensus guidelines developed
by over 20 Mayo clinic myeloma physicians which aims
to provide recommendations for the treatment of myeloma
patients [6]. Two key aspects to the guidelines, relevant to this
paper, exist. Firstly, themSMARTmodel has collated together
the multiple validated biological factors which influence
prognosis, and therefore risk, and classified them into 3
groups: tumour biology, tumour burden, and patient related
factors. From within the tumour biology category, which
is formulated through the use of conventional cytogenetics,
FISH andGEP, a risk stratification systemhas been composed
placing patients into a high-, standard-, or intermediate-risk
group (Table 2) [6]. The mSMART group recommend that
all myeloma patients undergo cytogenetic testing and risk
stratification at diagnosis as these groups have been validated
across multiple centres and correlate with a median OS of 3
years for high-risk, 4-5 years for intermediate-risk, and 8–10
years for standard-risk disease [17–21]. These risk groups can
therefore importantly help determine not only prognosis but
also the intensity and length of treatment regimes.
4. The RAG Model
As is evident, the inclusion of genetic information into
a myeloma risk stratification system is both required and
achievable at a given level.The biggest obstacle to progression
in this area is how best to interpret and use the large
amounts of complex data that the aforementioned molecular
techniques generate. Answers to this problem must soon
be developed as the accessibility, speed, and cost of the
techniques will soon mean they are available for utilisation
in the workup of a newly diagnosed myeloma patient. The
following subsection therefore outlines a proposed genetic
risk stratification model, developed as a concept, to try
Table 2:The mSMART risk stratification system in active myeloma
[6].
High risk Intermediate risk Standard risk
FISH FISH FISH
del(17p) t(4;14) t(4;14)
t(14;16) t(6;14)
t(14;20)
GEP Cytogenetic del(13) All other patients
High-risk
signature
Hypodiploidy
Plasma cell
labelling index
≥3%
and create a starting point for how genetic information,
particularly sequencing data, may be utilised.
4.1. RAG Model Categorisation System. Many groups
have produced different biological classification systems for
myeloma developed through a range of molecular techniques
[7, 22–24]. For the RAGmodel, a new classification system is
not proposed, but what is proposed is a novel categorisation
method to collate genetic aberrations under relevant
groups. Table 3 demonstrates the categories proposed and
identifies whether these represent an initiation/primary or
progression/secondary event, an important distinction as the
initiating/primary events contribute significantly towards
disease behaviour, as demonstrated by the difference between
hyperdiploidy and nonhyperdiploidy subtypes [5, 25, 26],
whereas progression/secondary events can initiate transition
to a more aggressive disease state and/or promote drug
resistance [5]. It is recognised that the categories for the
progression/secondary events are highly generalized; this
however is purposeful and is designed to promote simplicity
and interpretation, features that are essential if a genetic
model is to breech the gap between genetic research and the
clinical environment.
4.2. Candidate Genes for the RAG Model. Using conven-
tional cytogenetic and FISH techniques, it has long been
recognised that gross structural and numerical chromosomal
changes are important in defining myeloma risk. With the
recent employment of GEP and WGS/WES, however, the
important genes in these instances are being identified whilst
other salient genes, disrupted through more subtle structural
changes/mutations, are becoming apparent. With this, the
RAG model aims to expand on current systems of risk
stratification by incorporating individually mutated genes
deemed to be important in driving myeloma pathogenesis.
For this, the genes relevant to the categories outlined in
Table 3 are now listed in Table 4. It should be stated that in the
model certain genes, for example,MMSET, are listed twice, as
in these instances the gene may be both disrupted through
a gross karyotypic structural/numerical aberration or be
independently mutated and therefore relevant to another
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Table 3: RAG model categories.
RAG category Initiation/primaryevent
Progression/secondary
event
Hyperdiploidy
(Trisomies—1, 3, 5,
7, 9, 11, 15, 19, 21)
✓
t(4;14) ✓
t(6;14) ✓
t(11;14) ✓
t(14;16) ✓
t(14;20) ✓
+1q ✓
Del(1p) ✓
Del(11q) ✓
Del(12p) ✓
Del(13/13q) ✓
Del(14q) ✓
Del(16q) ✓
Del(17p) ✓
Secondary t(8;14) ✓
Bone disease ✓
Proliferation ✓
Apoptosis and
NF-𝜅B ✓
Differentiation ✓
DNA repair ✓
RNA editing ✓
Epigenetic ✓
category. This addition allows the model to be fully inclusive
by recognising that genes may be disrupted through multiple
mechanisms.
4.3. Calculating a RAG Score. The model for calculating
a RAG score is outlined in Figure 1, and, from this, it is
apparent that the aberrations categorised in Tables 3 and
4 are now stratified into a red group, worth an arbitrary
value of 3.0, an amber group worth 2.0, and a green
group worth 1.0. By inputting the corresponding genetic
aberrations from a patient sample, a mean RAG score can
be calculated for risk stratification. Using this system, it
is proposed that four stratified groups can be formulated.
Those scoring 1 to 1.5 are deemed low-risk, those scoring
1.5 to 2.0 are low-intermediate-risk, those scoring 2.0 to 2.5
are a high-intermediate-risk, and those scoring 2.5–3.0 are
high-risk (Table 5). This score is proposed as a pragmatic
means of stratifying the aggressiveness of myeloma between
a restrictive range of 1.0 and 3.0 based on genetic findings.
A mean method rather than a summative method has been
chosen as it is technique-independent and puts greater weight
towards the more important genetic aberrations as outlined
in the model. This is as opposed to a summative method
which would be technique-dependent, insofar as the more
extensively you analyse for, and detect, aberrations the higher
Table 4: RAG model categories and their candidate genes.
RAG category Candidate genes Reference
Hyperdiploidy
(Trisomies—1, 3, 5,
7, 9, 11, 15, 19, 21)
CCND1, CCND2,
CCND3 [22, 25]
t(4;14) FGFR3, MMSET [20, 23, 24, 27, 33]
t(6;14) CCND3 [7]
t(11;14) CCND1 [7]
t(14;16) c-MAF [24, 34, 35]
t(14;20) MAFB [21]
+1q CKS1B, ANP32E [4, 14, 36–39]
Del(1p) CDKN2C, FAF1,FAM46C [36, 37, 40, 41]
Del(11q) BIRC2, BIRC3 [36, 42, 43]
Del(12p) CD27 [12, 36]
Del(13/13q) RB1, DIS3 [7, 44–47]
Del(14q) TRAF3 [36, 42, 43]
Del(16q) CYLD, WWOX [36, 42, 43]
Del(17p) TP53 [7, 24, 48]
Secondary t(8;14) MYC [49, 50]
Bone disease DKK1, FRZB [51, 52]
Proliferation NRAS, KRAS, BRAF,MYC [10, 53]
NF-𝜅B
TRAF2, TRAF3, CYLD,
NFKB1, NFKB2, NIK,
TACI, LTBR, BIRC2,
BIRC3, WWOX, CD40
[10, 42, 43]
Differentiation XBP1, BLIMP1, IRF4 [10, 54]
DNA repair TP53, PARP1 [24, 48, 55]
RNA editing DIS3, FAM46C, LRRK2 [10, 36, 40]
Epigenetic KDM6A, KDM6B, MLL,MMSET, HOXA9 [10, 56, 57]
a score you would produce. It should be stated that the
score devised is relative to myeloma as a disease, where it
is known that even small degrees of genetic abnormality
can result in an aggressive phenotype and poor survival.
Therefore, the low-, intermediate-, and high-risk groups
should be viewed in light of typicalmyeloma survival times. A
particular mention is required for t(4;14), as historically this
has been considered a high-risk feature. However, with the
implementation of newer agents, especially the proteasome
inhibitor bortezomib, these patients are demonstrating far
greater survival [20, 27], and so it is proposed here that the
translocation be considered an intermediate-risk lesion.
4.4. Selection of RAG Model Categories and Genes. To deter-
mine the selected genes and categories to compile the RAG
model, the evidence from studies linking genetic aberrations
to prognosis/risk was reviewed. The criteria used to evaluate
the evidence was based on establishedmethods used by other
groups and is represented in Table 6 [28]. For a gene to have
been selected, it must have been independently supported by
grade A recommendation, with those aberrations linked to a
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Initiating event Progression event
Differentiation
t(14;16) Del(1p) Secondary t(8;14)
t(14;20)
Del(17p) RNA editing
Del(12p) DNA repair
Proliferation Bone disease
Del(16q) Del(14q)
t(4;14) Del(13/13q)
Del(11q) Epigenetic
t(6;14)
t(11;14)
Hyperdiploidy
3.0
2.0
1.0
NF-𝜅B
+1q
Figure 1: The RAG model. The genes and categories selected for
the RAG model are placed into their respective red, amber, and
green groups. To generate a RAG score, the average score for lesions
correlating between a patient sample and the model is calculated.
The RAG score is then used for risk stratification.
poor prognosis being placed into the red group, those linked
to superior survival placed into the green group, and those
of a neutral prognostic impact placed into the amber group.
This method was applied where possible; however, certain
genes, especially within the NF-𝜅B and epigenetic groups,
are included as they are deemed important due to functional
characterisation and mutational recurrence, as supported by
grade A recommendation; yet studies specifically assessing
their independent link to prognosis have not been conducted.
Thismay compromise a degree of accuracy at present, though
studies investigating these genes independently are likely to
become available soon, and as the RAG model is designed to
be a concept model, it is certainly adaptable and will require
modification in the future where appropriate.
4.5. Application of the RAG Model. It is envisaged that
cost and availability permitting, a model such as the RAG
model will be used both at diagnosis and at later disease
stages/relapse to build a genetic pattern over time. As it is
recognised that myeloma progresses in union with an ever-
changing genetic landscape through the advancement and
regression of clonal tides [29, 30], it appears likely that a
patient’s RAG score will alter in line with genetic changes.
This change in risk score, and newly identified aberrations,
would be accepted within the remit of the model’s applica-
tion and may help direct adjustments to therapies and/or
treatment intensities for patients along with restratifying
risk. In further reference to therapeutic guidance, it should
be stated that a patient’s RAG score will be interpreted
alongside the administered treatment regime as this may
allow patterns of genetic abnormalities to be identified which
could assist in determining resistance patterns. Furthermore,
taking account of disease progressionwhilst on treatment and
Table 5: RAG scores and their risk stratification groups.
RAG score RISK Stratification
2.5–3.0∗ High-risk∗
2.0–2.5∗∗ High-intermediate-risk∗∗
1.5–2.0∗∗ Low-intermediate-risk∗∗
1.0–1.5∗∗∗ Low-risk∗∗∗
∗Red color. ∗∗Amber color. ∗∗∗Green color.
Table 6: Classification system for levels of evidence and grades of
recommendation [28].
Type of evidence
Level I—meta-analysis of multiple, well-designed, controlled
studies. Randomized studies with low type 1 and type 2 errors
(high power) are also considered.
Level II—evidence obtained from at least one, well-designed
experimental study. Randomised trials with high type 1 and/or
type 2 errors (low power) are also considered.
Level III—well-designed, quasiexperimental studies such as
nonrandomised, controlled single-group, prepost, cohort, time, or
matched case-control series.
Level IV—well-designed, nonexperimental studies, such as
comparative and correlational descriptive and case studies.
Level V—case reports and clinical examples.
Grade of recommendation
Grade A—evidence of level I or consistent findings from multiple
levels II, III, and IV studies.
Grade B—evidence of levels II, III, or IV with generally consistent
findings.
Grade C—evidence of levels II, III, or IV but findings are
inconsistent.
Grade D—minimal or no systematic empirical evidence.
a short duration of response are recognised as therapy-related
high-risk factors which may represent additional nongenetic
factors to consider for prognosis [31, 32].
4.6. RAG “Pizza” Plots. To help visualize the RAG score and
facilitate a better understanding of its meaning in the clinical
environment, it is proposed that the score will be represented
as a RAG “pizza” plot, whereby the genetic categories are
displayed as colour plots as outlined in Figure 2. As a greater
“weight” is given to the higher-risk lesions, these represent
larger segments of the plot in comparison to lower-risk
lesions. It is proposed that a more detailed report would
be made alongside the RAG “pizza” plot for each patient
outlining the specific genes and mutations present within the
genome. Providing information on the specific mutations is
likely to have particular importance for treatment decisions,
especially in the future, as targeted therapies against specific
aberrations are likely to be available and will facilitate an era
of personalized cancer treatment.
4.7. Limitations to the RAG Model. It is recognised that by
simply stating candidate geneswithin theRAGmodel that the
system fails to outline the specific mutations relevant within
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3.0
3.0
3.0
3.0
2.0
RAG “pizza” plot
t(14;16)
Gain 1q
Loss 1p
Proliferation
High-risk
1.0
2.0
2.0
3.0
RAG “pizza” plot
Trisomies Epigenetic
Proliferation
Low-intermediate-risk
RAG score = 2.8 RAG score = 2.0
NF-𝜅B NF-𝜅B
Figure 2: RAG “pizza” plots. The RAG “pizza” plots are colour plots which represent how the RAG score will be presented. The size of the
segment each aberration represents is proportional to the “weighting” that lesion is given in calculating the RAG score; that is, a red group
lesion will be represented by a larger segment when compared to the segments of amber and green lesions. Representation of the RAG score
as a “pizza” plot helps to visualize the score and improve understanding.
that gene.This is important, as the functional consequence of
two different mutations within a gene may well be different.
Furthermore, it is recognised that synonymous mutations
may occur within genes and therefore impart no alteration
to protein structure. However, in a WGS/WES study by
Chapman et al., [10] a nonsynonymous/synonymous ratio of
39 : 0 was observed in significantly mutated genes and it is
therefore predicted that through the RAGmodel only includ-
ing pathogenically important and recurrently mutated genes
that the frequency of silentmutationswill be low.Despite this,
it is accepted that an algorithm, perhaps implemented along-
side genomic reporting, will be required to demonstrate the
functional importance of individualmutations. Furthermore,
it is accepted that the model does not perhaps accurately
reflect how genetic aberrations interact in vivo, as by using a
mean method the model does imply that a low-risk mutation
may ameliorate some of the influence of a high-risk lesion
to the risk outcome, a factor which seems unintuitive but
is at present unknown. Lastly, and most importantly, it is
recognised that the RAGmodel is yet to be clinically validated
and that the proposed model has been compiled by collating
and extrapolating the information from a range of studies
each with varying designs and limitations. It is however
predicted that suitable data sets, that is, those using a range of
molecular techniques including WGS/WES against survival,
will soon become available and will provide the opportunity
to clinically validate the RAGmodel and allow conclusions to
be made on the accuracy of the system.
5. Conclusion
The RAG model is presented here as a concept for myeloma
risk stratification system based on the genetic characteristics
of the disease. The justification for the need of such a model
is apparent from reviewing the literature which demonstrates
that the underlying genetic makeup of an individual’s disease
contributes significantly towards behaviour and outcome
and can be used to inform risk. The RAG model has been
designed to begin the process of bridging the gap between
experimental research and clinical medicine whereby there
is a necessity to simplify large amounts of complex data
into a useful and formative structure. Although principally
designed to inform disease risk, it is envisaged that in the
future a model such as the RAG model would be able to
also contribute towards the identification of new disease
biomarkers and therapeutic targets and aid in the genetic
categorisation and diagnosis of myeloma disease subtypes.
In conclusion, despite its lack of clinical validation and
optimisation, we believe that the RAG model has enormous
potential to simplify otherwise complex genetic data to guide
clinicians and improve treatment outcomes for patients. For
this reason, we wish to present the model as a prototypic
concept of how state-of-the-art genomic data can comple-
ment other established technologies to usher in an era of
personalized myeloma medicine.
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